Portola Pharmaceuticals (NASDAQ:PTLA) is set to issue its quarterly earnings data after the market closes on Wednesday, November 7th. Analysts expect the company to announce earnings of ($1.54) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($1.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($0.12). The company had revenue of $4.01 million for the quarter, compared to the consensus estimate of $6.35 million. Portola Pharmaceuticals had a negative net margin of 1,503.29% and a negative return on equity of 111.64%. The company’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.22) EPS. On average, analysts expect Portola Pharmaceuticals to post $-6 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Portola Pharmaceuticals stock opened at $19.01 on Wednesday. The company has a debt-to-equity ratio of 0.91, a quick ratio of 6.59 and a current ratio of 6.69. Portola Pharmaceuticals has a 1 year low of $18.56 and a 1 year high of $56.70.
PTLA has been the topic of several recent analyst reports. Zacks Investment Research cut shares of Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, July 19th. Cowen reiterated a “buy” rating on shares of Portola Pharmaceuticals in a research report on Thursday, August 9th. Oppenheimer set a $70.00 price objective on shares of Portola Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 9th. Credit Suisse Group reiterated an “underperform” rating and set a $28.00 price objective (down previously from $49.00) on shares of Portola Pharmaceuticals in a research report on Friday, August 10th. Finally, Citigroup reduced their price objective on shares of Portola Pharmaceuticals from $64.00 to $50.00 and set a “buy” rating on the stock in a research report on Friday, August 10th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $48.29.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. The company's two FDA-approved medicines are Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo), an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness.
Recommended Story: How a Put Option Works
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.